UNC Lineberger Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).
UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.
UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.
Top-decile sponsor footprint
UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
366 total, page 5 of 8
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
NCT03076333
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
NCT03446157
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
NCT03442569
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
NCT03418792
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
NCT03488862
Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging
NCT03761706
mHealth Physical Activity Intervention for Survivors of Adolescent and Young Adult Cancers
NCT03386383
Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant Population
NCT04025190
Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors
NCT03196037
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
NCT03263442
Enhancing Source Credibility in Tobacco Regulatory Communications
NCT03339206
Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program
NCT04350788
A Culturally-adapted Colorectal Cancer Screening Decision Aid Designed for American Indians
NCT03569761
A Patient Portal Tool, E-assist, for Supporting CRC Screening
NCT02798224
Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients
NCT03156244
Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
NCT03089606
Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases
NCT03281720
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
NCT03672396
Get REAL and HEEL Research Program
NCT03760536
18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients
NCT03546556
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
NCT03077243
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
NCT02844400
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
NCT02768701
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
NCT02700022
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
NCT02684461
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
NCT02768792
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
NCT02609503
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
NCT02690558
Geriatric Assessment Reporting in Real Time (GARRT) in Non-electively Hospitalized Older Cancer Patients
NCT03951090
Effect of Human Papillomavirus Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3
NCT02651883
Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease
NCT02781025
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
NCT02786628
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
NCT03407430
A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
NCT02767362
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
NCT02585973
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
NCT02682199
Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study
NCT02682836
Fitness in Allogeneic Stem Cell Transplantation
NCT02564458
Pre-Post Study for Supporting Appropriate Implementation of Lung Cancer Screening
NCT03077230
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
NCT02334527
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
NCT02276560
Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older
NCT02328313
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
NCT02281955
The Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Chemotherapy
NCT02574897
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
NCT02124707
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older
NCT02191982
Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound
NCT02175628
Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer
NCT02191969
The CARE Program: CAncer REhabilitation Pilot Study for Older Adults
NCT02306252
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
NCT02138617
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 86 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the UNC Lineberger Comprehensive Cancer Center pipeline
79 recruiting of 366 indexed (22% open); 209 completed (57%).
Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 366 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Merck Sharp & Dohme · 22% recruiting · 558 trials
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 22% recruiting · 60 trials
- AbbVie · 21% recruiting · 526 trials
Related
What to do with this UNC Lineberger Comprehensive Cancer Center page
366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.
- 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets.Report a data error.